Endometrial cancer (EC) ranks as the second most prevalent gynecologic malignancy globally, with approximately 189,000 new ...

Here are the top 5 most common forms of cancers that can hit your immune system as soon as you cross 30. Check out the cancer ...

The addition of radiation to chemotherapy did not improve overall survival in patients with locally advanced endometrial cancer, a recent phase 3 trial found.

Cancer rates are declining, but young women are being diagnosed more frequently. Learn about the current trends and research ...

The EC has approved GSK's Jemperli (dostarlimab) combined with chemotherapy for primary advanced or recurrent endometrial ...

Imfinzi recommended for approval in European Union for the treat of adults with limited-stage small cell lung cancer ...

Often referred to as the "change of life," menopause marks a significant change for women. As you approach your mid-40s, you may begin to notice subtle shifts in your body, such as irregular ...

“Clinicians should be aware of these rising incidence trends and prioritize educating young women about the risk factors and symptoms of endometrial cancer, while actively listening to and ...

Lenvima plus Keytruda did not significantly improve survival or progression-free survival compared to chemotherapy in advanced endometrial cancer. The study involved 842 patients, with no new safety ...

GSK's Jemperli wins EU approval for broader use in advanced endometrial cancer, showing improved survival and significant trial results.